Skip to main content
. Author manuscript; available in PMC: 2023 Jun 16.
Published in final edited form as: Neurocrit Care. 2021 Jan 6;35(1):255–261. doi: 10.1007/s12028-020-01161-5

Table 2.

Outcomes for all patients included

Andexxa
N=28
4F-PCC
N=16
p P adjusted
CT Scan Stability
 All Included Patients
  Stable CT scan at 6 hr* 21 (78) 10 (71) 0.71 0.62
  Stable CT scan at 24 hr± 15 (88) 6 (60) 0.15 0.10
 Spontaneous IPH only
  Stable CT scan at 6 hr 13 (87) 4 (100) 1.00 0.91
  Stable CT scan at 24 hrǁ 7 (87) 4 (100) 1.00 0.74
Spontaneous IPH Hematoma volume (mL)
 Hematoma Volume at 6 h post reversal 9.3 [6.9 – 26.4] 10 [9.4 – 22.1] 0.67 0.997
 Hematoma volume at 24 hours post reversalǁ 9.2 [6.1 – 18.8] 9.9 [9.4 – 21.1] 0.57 1
Unstable CT scan at 24 hr±
 Non-traumatic ICH
  IVH without IPH 1 0 1
 Traumatic ICH
  SDH 0 1 0.242
  Multicompartment bleed 1 3
Good Outcome (mRS <=3) on discharge 10 (36) 6 (38)  1  0.81
Mortality
 Death/Hospice on discharge 11 (39) 6 (38) 1 0.86
Length of Stay
 Hospital LOS 7 [4 – 15] 6 [2 – 11] 0.20
 ICU LOS 2 [1 – 4] 4 [1 – 8] 0.38
VTE Events
 Deep Venous Thrombosis on discharge 2 (7) 0 (0.0) 0.53
Disposition
 ARF 5 (18) 1 (6) 0.71
 Dead/Hospice 11 (39) 6 (38)
 Home 6 (21) 4 (25)
 SNF 6 (21) 5 (31)

Nominal data presented as n (%) and continuous data as median [IQR]

ARF, acute rehab facility; CT, computed tomography; ICU, intensive care unit; IPH, intraparenchymal hemorrhage; LOS, length of stay; mRS, Modified Rankin Score; SNF, skilled nurse facility; VTE, venous thromboembolic.

*

Evaluable CT-scans AA=27, 4F-PCC=14;

±

Evaluable CT-scans AA=17, 4F-PCC=10;

Evaluable CT-scans AA=15, 4F-PCC=4;

ǁ

Evaluable CT-scans AA=8, 4F-PCC=4